Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.

Felipe K HurtadoFilippo de BraudJavier De Castro CarpeñoMaria Jose de Miguel LukenDing WangJeffrey ScottYvonne Y LauTracey McCullochMorten Mau Sorensen

Published in: Cancer chemotherapy and pharmacology (2021)

Ceritinib is a strong CYP3A inhibitor and a weak CYP2C9 inhibitor. These findings should be reflected as actionable clinical recommendations in the prescribing information for ceritinib with regards to concomitant medications whose pharmacokinetics may be altered by ceritinib.

Keyphrases

adverse drug
primary care
clinical practice
tyrosine kinase